Engineered immune cells take on sarcoma in early trial
NCT ID NCT00902044
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether specially engineered immune cells (HER2-specific CAR T cells) can safely treat advanced sarcoma that has not responded to standard treatments. Up to 36 participants will receive an infusion of their own modified T cells, with some also getting chemotherapy beforehand to help the cells work better. The main goal is to find a safe dose and see if the therapy can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HER2-specific CAR T cells
What this could lead to
If it works, this could point toward a new treatment option for advanced sarcoma that has not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 36 participants, so it is too small to prove effectiveness. The treatment may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States